AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04054232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High PAD risk Alert
Description: In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~1. Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~2. What peripheral artery disease is and why diagnosis may be important~3. Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~4. The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included.
Study NCT05066438 — intervention group
Intervention type: BEHAVIORAL
Intervention: Antenatal hand expression
Description: Standardized counselling and provision of information/resources on the practice of antenatal hand expression to encourage milk let down and colostrum production/collection.
Study NCT06558877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmacist-led multifaceted intervention
Description: Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol.~Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring.
Study NCT06558877 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional health education
Description: The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT06445192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06445192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Attend group counseling
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive aerobic and resistance exercise intervention via telehealth
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbit
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbit
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06294743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve neuroprolotherapy
Description: Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06445192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Receive aerobic and resistance exercise intervention via telehealth
Study NCT06362486 — intervention group
Intervention type: OTHER
Intervention: Severity of infection, time of infection.
Description: Severity of infection, time of infection.
Study NCT06362486 — intervention group
Intervention type: OTHER
Intervention: Mental health assessment
Description: Mental health assessment
Study NCT06362486 — intervention group
Intervention type: OTHER
Intervention: biological
Description: Prognostic immunologic factors associated with cognitive impairment in children born of sars-cov-2-infected mothers.
Study NCT05491226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
Study NCT05491226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.
Study NCT05491226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
Study NCT03337997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
Study NCT06294743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
Study NCT06449274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
Study NCT06449274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.
Study NCT06449274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed medical treatment
Description: All individuals will receive guideline-directed medical treatment.
Study NCT05689762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle counseling and E-health support
Description: Promotion of healthy lifestyle behaviors through counseling and access to E-health platform
Study NCT04680117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max
Study NCT04680117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sample
Description: Saliva sample by subject at J0
Study NCT04680117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal
Description: Nasal brushing by subject at J0
Study NCT05661188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Tiraglolumab
Description: All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
Study NCT06218927 — intervention group
Intervention type: OTHER
Intervention: QoL monitoring
Description: QoL questionnaire
Study NCT05507801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Milkshake
Description: A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
Study NCT05507801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Milkshake
Description: A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
Study NCT05658757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular sweetened commercial foods
Description: This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do.
Study NCT05658757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose sweetened commercial foods
Description: This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits.
Study NCT05658757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole and minimally processed and sweetened foods
Description: Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines.
Study NCT05548478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transepithelial PRK/MMC
Description: transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
Study NCT05548478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-Assisted PRK/MMC
Description: photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
Study NCT06351202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
Study NCT04205435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous HSC
Description: gene edited autologous hematopoietic stem cells with β-globin restoration
Study NCT05071131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: 1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
Study NCT05071131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
Study NCT06272175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain Activity
Description: PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
Study NCT06272175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain Activity
Description: Weight-bearing on the hemiplegic hand with extended elbow in standing position
Study NCT05223153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence tomography angiography
Description: Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
Study NCT04718844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection
Study NCT04886973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.
Description: Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
Study NCT04718844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride for s.c. injection
Study NCT06074042 — intervention group
Intervention type: OTHER
Intervention: previous pulmonary tuberculosis
Description: Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
Study NCT04963842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of bio-plastic food packaging material and avoidance of plastic food packaging material
Description: The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
Study NCT05607264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinsiotaping
Description: Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
Study NCT05607264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-controlled VR games
Description: Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
Study NCT05607264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: patients received conventional treatment for chronic shoulder impingement syndrome only.
Study NCT05607264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: patients received conventional treatment for chronic shoulder impingement syndrome only.
Study NCT05817747 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dialogue support tool
Description: The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
Study NCT05817747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialogue support tool
Description: The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
Study NCT06351683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ (mitoquinol mesylate)
Description: MitoQ is an antioxidant molecule designed to target cell stress
Study NCT06351683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
Study NCT05020561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group life-coaching
Description: Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document.
Study NCT05020561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual life-coaching
Description: In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
Study NCT03872505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
Study NCT03872505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
Study NCT03872505 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.
Study NCT03872505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV administration weekly for 12 weeks
Study NCT03872505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV administration weekly for 12 weeks
Study NCT03872505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV administration every week for 12 weeks
Study NCT03872505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV administration every week for 12 weeks
Study NCT05082779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally
Study NCT04892368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based supervised exercise program
Description: Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
Study NCT05639244 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Time restricted eating (TRE)
Description: Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
Study NCT05639244 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular diet
Description: Participants have to consume their regular diet within an unrestricted time period for 2 weeks
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzoparib
Description: Fluzoparib
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant
Study NCT06561022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant
Study NCT06102330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HomeVENT decision support tool
Description: Web-based decision support tool that describes diverse family experiences with making decisions about pediatric chronic home ventilation
Study NCT05045950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine -Twice Daily or Extended Release
Description: Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4).